microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac
Company profile
Ticker
MBOT
Exchange
Website
CEO
Harel Gadot
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CYTOTHERAPEUTICS INC/DE, STEMCELLS INC
SEC CIK
Corporate docs
IRS number
943078125
MBOT stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
16 Apr 24
8-K
Other Events
15 Apr 24
424B3
Prospectus supplement
4 Apr 24
EFFECT
Notice of effectiveness
4 Apr 24
S-1/A
IPO registration (amended)
1 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Departure of Directors or Certain Officers
26 Feb 24
S-1
IPO registration
20 Feb 24
424B3
Prospectus supplement
30 Jan 24
8-K
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
30 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.34 mm | 1.34 mm | 1.34 mm | 1.34 mm | 1.34 mm | 1.34 mm |
Cash burn (monthly) | 1.46 mm | 249.75 k | 848.00 k | 904.58 k | 551.67 k | 764.58 k |
Cash used (since last report) | 9.99 mm | 1.71 mm | 5.79 mm | 6.18 mm | 3.77 mm | 5.22 mm |
Cash remaining | -8.66 mm | -371.61 k | -4.46 mm | -4.85 mm | -2.43 mm | -3.89 mm |
Runway (months of cash) | -5.9 | -1.5 | -5.3 | -5.4 | -4.4 | -5.1 |
Institutional ownership, Q3 2023
8.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.20 bn |
Total shares | 1.21 mm |
Total puts | 1.30 k |
Total calls | 13.90 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 261.34 k | $363.26 mm |
Gadot Harel | 214.71 k | $2.17 mm |
BLK Blackrock | 137.81 k | $191.55 mm |
Renaissance Technologies | 123.59 k | $172.00 k |
AlphaCentric Advisors | 100.00 k | $139.00 mm |
Geode Capital Management | 92.40 k | $128.47 mm |
Citadel Advisors | 51.54 k | $71.64 mm |
BK Bank Of New York Mellon | 51.35 k | $71.37 mm |
MS Morgan Stanley | 40.04 k | $55.65 mm |
STT State Street | 26.07 k | $36.24 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Gadot Harel | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.25 | 79,567 | 99.46 k | 79,567 |
22 Feb 24 | Juan Diaz-Cartelle | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 17,500 | 22.20 k | 17,500 |
22 Feb 24 | Simon Sharon | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 17,500 | 22.20 k | 17,500 |
22 Feb 24 | Simon Sharon | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 17,500 | 22.20 k | 17,500 |
22 Feb 24 | Rachel Vaknin | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 17,500 | 22.20 k | 17,500 |
22 Feb 24 | Rachel Vaknin | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 17,500 | 22.20 k | 17,500 |
22 Feb 24 | Gadot Harel | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 80,000 | 101.47 k | 80,000 |
22 Feb 24 | Gadot Harel | Stock Option Common Stock, par value $0.01 per share | Grant | Acquire A | No | No | 1.2684 | 80,000 | 101.47 k | 80,000 |
News
HC Wainwright & Co. Maintains Buy on Microbot Medical, Lowers Price Target to $7
17 Apr 24
HC Wainwright & Co. Maintains Buy on Microbot Medical, Lowers Price Target to $7
16 Apr 24
Microbot Medical Shares Status Following Recent Geopolitical Events; Says All Regulatory, Clinical, Operational And Pre-Commercial Activities Continue To Stay On Track Despite The On-Going Situation In Israel
15 Apr 24
Microbot Medical Q4 EPS $(0.26) Misses $(0.25) Estimate
27 Mar 24
Looking Into Microbot Medical's Recent Short Interest
2 Feb 24
Press releases
Microbot Medical Shares Status Following Recent Geopolitical Events
15 Apr 24
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
5 Feb 24
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
30 Jan 24